Please ensure Javascript is enabled for purposes of website accessibility

Curaleaf Falls by Over 4% on Q1 Results

By Eric Volkman - May 10, 2021 at 7:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The quarter wasn't necessarily a bad one, but a big new competitor looms.

Marijuana stock Curaleaf (CURLF 1.20%) didn't get a lot of investors high Monday, despite delivering better-than-expected revenue for its inaugural quarter of 2021.

For the marijuana company's first quarter, the figures for which were published that morning, it booked $260 million in revenue, 170% higher on a year-over-year basis and 13% better than the fourth-quarter 2020 number. It was also a new all-time Q1 record for Curaleaf.

The multi-state operator's (MSO) net loss was $17.2 million, or $0.03 per share. That was slightly worse than the Q1 2020 deficit of just over $15 million, but a big improvement over the previous quarter's $35.1 million shortfall. On the marijuana industry's preferred profitability metric -- non-GAAP (adjusted) EBITDA -- Curaleaf earned $62.6 million, against the year-ago result of $20 million and Q4's $53.8 million.

Closeup of a $100 bill with a marijuana leaf atop it.

Image source: Getty Images.

On average, analysts tracking the stock were expecting only $254 million in revenue; however, they thought the company would post a net loss of $0.01 per share.

But Curaleaf has a keen eye trained on the future. The company quoted its CEO Boris Jordan as pointing out that "The recent approvals of adult-use cannabis in New Jersey and New York, which are states where Curaleaf has a leading market share, will unlock vast new markets, worth an estimated $2.1 billion and $5 billion in sales, respectively."

Investors, however, might be more concerned that a giant competitor for Curaleaf is about to arise. Monday morning, Trulieve Cannabis (TCNNF 1.08%) and Harvest Health & Recreation (HRVSF) announced the former is acquiring the latter in a (relatively) massive $2.1 billion all-stock deal. The combined company will have 126 dispensaries under its wing, eclipsing Curaleaf's tally of 106.

This was likely the driving factor in Curaleaf stock's 4.3% fall Monday, against the S&P 500's decrease of only 1%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Trulieve Cannabis Corp. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
$5.95 (1.20%) $0.07
Trulieve Cannabis Stock Quote
Trulieve Cannabis
$13.06 (1.08%) $0.14
Harvest Health & Recreation Inc. Stock Quote
Harvest Health & Recreation Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.